A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Clinical trial NCT01539512 · COMPLETED
Trial details
- NCT number
- NCT01539512
- Sponsor
- Gilead Sciences
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2012-04-01
- Primary completion
- 2013-10-01
- Enrollment
- 220
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.